Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · IEX Real-Time Price · USD
18.66
-0.14 (-0.74%)
At close: Jul 19, 2024, 4:00 PM
18.65
-0.01 (-0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Zai Lab Revenue
Zai Lab had revenue of $291.07M in the twelve months ending March 31, 2024, with 25.94% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $87.15M with 38.78% year-over-year growth. In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth.
Revenue (ttm)
$291.07M
Revenue Growth
+25.94%
P/S Ratio
6.35
Revenue / Employee
$133,826
Employees
2,175
Market Cap
1.85B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
Dec 31, 2018 | 129.00K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Warby Parker | 697.80M |
Harmony Biosciences Holdings | 617.51M |
NeoGenomics | 610.66M |
Veracyte | 375.47M |
Mirum Pharmaceuticals | 224.00M |
Ligand Pharmaceuticals | 118.31M |
RxSight | 101.10M |
ZLAB News
- 6 days ago - Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Business Wire
- 6 days ago - Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy - Business Wire
- 12 days ago - Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 - Business Wire
- 12 days ago - Aldinger Company Acquires J&J Calibrations - Business Wire
- 5 weeks ago - Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D - Business Wire
- 2 months ago - Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis - Business Wire
- 2 months ago - Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China - Business Wire
- 2 months ago - Zai Lab Announces Participation in May and June Investor Conferences - Business Wire